These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 12620735)

  • 81. Time to lower cholesterol: the potential effect of cholesterol reduction on the incidence of cardiovascular disease.
    Plant AJ; Pierce JP; Rushworth RL; Goldstein GB
    Med J Aust; 1988 Jun; 148(12):627-9. PubMed ID: 3380043
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Mobile Work Site Health Promotion Programs can reduce selected employee health risks.
    Aldana SG; Jacobson BH; Harris CJ; Kelley PL
    J Occup Med; 1993 Sep; 35(9):922-8. PubMed ID: 8229345
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Cost-effectiveness analysis of salt reduction policies to reduce coronary heart disease in Syria, 2010-2020.
    Wilcox ML; Mason H; Fouad FM; Rastam S; al Ali R; Page TF; Capewell S; O'Flaherty M; Maziak W
    Int J Public Health; 2015 Jan; 60 Suppl 1():S23-30. PubMed ID: 24972676
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cost-effectiveness of the North Karelia Hypertension Program. 1972-1977.
    Nissinen A; Tuomilehto J; Kottke TE; Puska P
    Med Care; 1986 Aug; 24(8):767-80. PubMed ID: 3090379
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Investing in health wisely. The role of needs-based technology assessment.
    Jamison DT; Saxenian H; Bergevin Y
    Int J Technol Assess Health Care; 1995; 11(4):673-84. PubMed ID: 8567199
    [TBL] [Abstract][Full Text] [Related]  

  • 86. World military expenditures and global cardiovascular mortality.
    Brenner MH
    J Public Health Policy; 2016 Feb; 37(1):20-35. PubMed ID: 26675148
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Recommendation to Reduce Patients' Blood Pressure and Cholesterol Medication Costs.
    Fielding JE; Rimer BK; Johnson RL; Orleans CT; Calonge N; Clymer JM; Glanz K; Goetzel RZ; Green LW; Ramirez G; Pronk NP;
    Prev Chronic Dis; 2015 Nov; 12():E209. PubMed ID: 26605709
    [No Abstract]   [Full Text] [Related]  

  • 88. Epidemiology and costs of hypertension-related disorders.
    Leone A; Landini L; Leone A
    Curr Pharm Des; 2011; 17(28):2955-72. PubMed ID: 21861839
    [TBL] [Abstract][Full Text] [Related]  

  • 89. 2014 dietary salt fact sheet of the World Hypertension League, International Society of Hypertension, Pan American Health Organization technical advisory group on cardiovascular disease prevention through dietary salt reduction, the World Health Organization collaborating centre on population salt reduction, and World Action on Salt & Health.
    Campbell NR; Lackland DT; Niebylski ML
    J Clin Hypertens (Greenwich); 2015 Jan; 17(1):7-9. PubMed ID: 25265529
    [No Abstract]   [Full Text] [Related]  

  • 90. Cost effectiveness of lowering cholesterol. Full treatment of the costs and benefits is needed.
    Wierzbicki AS; Reynolds TM
    BMJ; 1996 Nov; 313(7065):1143; author reply 1144. PubMed ID: 8916709
    [No Abstract]   [Full Text] [Related]  

  • 91. The modifiable burden of worldwide mortality from cardiovascular diseases.
    Huxley RR; Perkovic V
    Lancet Diabetes Endocrinol; 2014 Aug; 2(8):604-6. PubMed ID: 24842600
    [No Abstract]   [Full Text] [Related]  

  • 92. Scaling up chronic disease prevention interventions in lower- and middle-income countries.
    Gaziano TA; Pagidipati N
    Annu Rev Public Health; 2013; 34():317-35. PubMed ID: 23297660
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The hidden epidemic of cardiovascular disease.
    Lancet; 1998 Dec; 352(9143):1795. PubMed ID: 9851373
    [No Abstract]   [Full Text] [Related]  

  • 94. Cost-effectiveness of cardiovascular disease spending.
    Miller G; Cohen JT; Roehrig C
    J Am Coll Cardiol; 2012 Nov; 60(20):2123-4. PubMed ID: 23137531
    [No Abstract]   [Full Text] [Related]  

  • 95. Strategic challenges in the prevention of cardiovascular disease.
    Patel KC; Minhas R; Lincoln P; Dhillon RK
    J R Soc Med; 2008 Mar; 101(3):105-7. PubMed ID: 18344465
    [No Abstract]   [Full Text] [Related]  

  • 96. Point-of-care testing for the analysis of lipid panels: primary care diagnostic technology update.
    Plüddemann A; Thompson M; Price CP; Wolstenholme J; Heneghan C
    Br J Gen Pract; 2012 Mar; 62(596):e224-6. PubMed ID: 22429442
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Government intervention in cardiovascular disease--help or hindrance? A Swedish viewpoint.
    Jönsson B
    Cardiology; 1994; 85 Suppl 1():90-5. PubMed ID: 7743541
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Estimating the global burden of disease of mild mental retardation and cardiovascular diseases from environmental lead exposure.
    Fewtrell LJ; Prüss-Ustün A; Landrigan P; Ayuso-Mateos JL
    Environ Res; 2004 Feb; 94(2):120-33. PubMed ID: 14757375
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Economic effectiveness of prophylactic and therapeutic measures in cardiovascular diseases].
    Roĭtman MP; Lunskaia LL
    Sov Zdravookhr; 1982; (5):50-4. PubMed ID: 6808669
    [No Abstract]   [Full Text] [Related]  

  • 100. Impact of World Hypertension Day.
    Chockalingam A
    Can J Cardiol; 2007 May; 23(7):517-9. PubMed ID: 17534457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.